Disc Medicine, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Disc Medicine, Inc. (IRON) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $100.00 thousand for the 1-month period ending 2023-11-30, per its 10-K filed 2024-03-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-21
- 2023-11-30: Operating Lease, Right-of-Use Asset, Amortization Expense 1 month $100.00K.
- 2023-09-30: Operating Lease, Right-of-Use Asset, Amortization Expense 1 month $200.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 1 month |
|---|---|
| 2023-11-30 | $100.00K 10-K · filed 2024-03-21 |
| 2023-09-30 | $200.00K 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |